A multicenter prospective study to assess the impact of physician's reinforcement on the subject's compliance and persistence on treatment using feedback on bone markers in previously undiagnosed postmenopausal osteoporotic women treated with risedronate [risedronic acid].

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Sep 2006

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risedronic acid (Primary)
Indications Postmenopausal osteoporosis
Focus Therapeutic Use
Acronyms IMPACT
Sponsors Sanofi

Most Recent Events

14 Sep 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight